FDA/NIH dental MOU
This article was originally published in The Gray Sheet
Executive Summary
Memorandum of understanding between FDA and the National Institutes of Health's National Institute of Dental Research has as its "principal goal" the reduction of time between the research and development phase of a dental product's life cycle and its commercial availability, FDA says in a June 2 Federal Register notice. The MOU will "facilitate interactions between" NIDR and the agency regarding "improvements in the quality and relevance of pre-clinical and clinical research" on products for use in oral health care. By enhancing the quality of product-related research, the organizations will "facilitate and improve premarket evaluations"...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.